Assessment of DHA On Reducing Early Preterm Birth

Completed · Phase 3 · Has a placebo group

Conditions studied: Preterm Birth

In brief

The purpose of this study is to determine if giving a larger amount of DHA than currently included in some prenatal supplements can reduce early preterm birth (birth before 34 weeks of pregnancy).

Key facts

Study ID

NCT02626299

Run by

University of Kansas Medical Center

People needed

1100

Starts

2016-06-08

Expected to finish

2020-10-05

Last updated by the study team

2021-03-30

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Pregnant females 18 years and older 12 to 20 weeks gestation at study entry
• Agree to consume study capsules and a typical prenatal supplement of 200 mg DHA
• Available by telephone
• Able to speak and read in either English or Spanish language

You may not qualify if…

• Expecting multiple infants
• Gestational age at baseline <12 weeks or >20 weeks
• Unable or unwilling to agree to consume capsules until delivery
• Unwilling to discontinue use of another prenatal supplement that contains greater than or equal to 200 mg DHA per day
• Women with allergy to any component of DHA product (including algae), soybean oil or corn oil

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States
• University of Cincinnati — Cincinnati, Ohio, United States
• Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.